Information Provided By: 
Fly News Breaks for March 1, 2017
CEMP
Mar 1, 2017 | 09:13 EDT
Janney Capital analyst Debjit Chattopadhyay said that until Cempra has clarity from the FDA on the "once promising" SoliThera, which is not expected until the third quarter of this year, that its shares are likely to trade below cash. He lowered his fair value estimate on Cempra shares to $5 from $8 based on the lack of regulatory and commercial visibility and keeps a Neutral rating on the name.
News For CEMP From the Last 2 Days
There are no results for your query CEMP
